1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Surgical Science Sweden AB

Surgical Science Sweden AB

5.16
EUR
+0.01
(+0.10%)
0.16EPS
17.55P/E
147.57MMarket Cap
Nov 12Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.9
3.62
2.97
2.7
3.6
3.05
8.63
15.8
17.33
17.33
19.45
20.04
Basic EPS, GAAP
0.07
0.23
-0.13
-0.19
0.45
0.45
2.03
3.7
4.59
2.58
1.31
1.83
Free Cash Flow per Basic Share
-0.03
0.12
-0.06
-0.07
1.64
0.42
0.58
1.87
3.81
1.76
0.6
1.63
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.81
0.83
3.42
3.26
11.95
12.38
70.57
83.39
85.16
94.63
83.74
89.19
Tangible Book Value per Share
-0.36
-0.45
2.08
2.01
2.22
3
5.74
9.67
14.31
17.66
17.54
19.36
Basic Weighted Avg Shares
24
14
19
24
28
34
42
51
51
51
51
51
Sales/Revenue/Turnover
46
52
57
66
102
105
367
803
883
884
992
1,022
Operating Margin (%)
3.69
-0.44
-7.31
-6.19
14.95
19.06
15.41
20.25
21.43
16.32
6.94
12.02
Depreciation Expense
7
9
10
10
15
17
34
52
56
61
83
- -
Net Income, GAAP
2
3
-3
-5
13
16
86
188
234
132
67
93
Effective Tax Rate (%)
- -
- -
- -
- -
17.38
20.62
- -
9.7
12.78
16.73
33.27
26.11
Profit Margin (%)
3.47
6.3
-4.49
-6.88
12.41
14.89
23.52
23.42
26.5
14.89
6.73
9.11
Working Capital
11
2
45
44
73
102
385
520
756
913
892
960
LT Debt
22
19
4
4
2
2
12
15
40
57
56
- -
Total Equity
20
20
83
79
402
427
3,585
4,236
4,345
4,829
4,273
4,551
Return on Invested Capital (%)
- -
- -
- -
- -
5.01
3.72
- -
3.73
3.8
2.57
0.99
2.05
Return on Capital (%)
- -
- -
- -
- -
5.17
3.85
- -
4.82
5.43
2.94
1.54
2.1
Return on Common Equity (%)
- -
16.39
-4.98
-5.56
5.24
3.77
4.3
4.81
5.45
2.87
1.47
2.1

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
2
3
LT Borrowings
- -
- -
- -
LT Finance Leases
56
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
1,672
1,556
1,635

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,185
1,187
1,260
Cash, Cash Equivalents & STI
616
668
658
Accounts Receivable, Net
137
123
127
Inventories
206
207
234
Total Current Liabilities
293
267
300
Payables & Accruals
- -
- -
- -
ST Debt
2
2
3
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
148.1%
151.97%
-11.51%
Free Cash Flow
-288.47%
67.79%
-66.04%
Net Income, GAAP
14.81%
100.42%
-49.24%
Sales/Revenue/Turnover
48.66%
78.24%
12.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
188
212
232
252
884
2025
251
209
264
269
992
2026
235
255
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.47
0.56
0.84
0.71
2.58
2025
0.65
-0.39
0.4
0.65
1.31
2026
0.37
0.41
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tom Englund
Full Time Employees
313
Sector
Health technology
Industry
Medical specialties
Address
Drakegatan 7 A, 3 tr. Gothenburg VG Sweden 412 50
IPO Date
Jun 19, 2017
Website
surgicalscience.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Surgical Science Sweden AB (publ) develops, manufactures and markets virtual reality simulators and software solutions for evidence-based medical training focused on minimally invasive surgery, endoscopy, ultrasound and team-based procedures; core products include the LapSim laparoscopic training system with modules from basic navigation to advanced suturing, EndoSim for endoscopic exercises including scope handling and loop reduction, TeamSim for operating room team communication and crisis management, and ultrasound simulation technologies; the company also provides customized simulation solutions for medical device companies developing instruments and offers ready-to-use simulators with evidence-based curricula for healthcare professionals. Founded in 1999 and headquartered in Gothenburg, Sweden, Surgical Science operates globally across Europe, North America, South America and Asia, serving teaching hospitals, clinics, medical training centers and MedTech partners with over 8,000 systems delivered and more than 400 validation studies. The company has expanded through strategic acquisitions including Simbionix, Mimic Technologies, SenseGraphics and, most recently, Intelligent Ultrasound Group PLC in December 2024 for approximately SEK 630 million, which strengthens its ultrasound simulation portfolio, establishes a UK research and development hub in Cardiff and enhances commercial presence in the UK market with expected annual cost synergies of SEK 21-28 million.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Surgical Science Sweden AB (publ) (SUSRF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Surgical Science Sweden AB (publ) (SUSRF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Surgical Science Sweden AB (publ) (SUSRF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Surgical Science Sweden AB (publ) (SUSRF) Analyst/Investor Day Transcript